CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
Jin Hyoung Kang, Jung Hye Kwon, Yun-Gyoo Lee, Keon Uk Park, Ho Jung An, Joohyuk Sohn, Young Mi Seol, Hyunwoo Lee, Hwan-Jung Yun, Jin Seok Ahn, Ji Hyun Yang, Hunho Song, Dong-Hoe Koo, Jin Young Kim, Gun Min Kim, Hwa Jung Kim
Cancer Research and Treatment. 2020;52(3):907-916.   Published online 2020 March 18    DOI: https://doi.org/10.4143/crt.2019.713

Excel Download

Ramosetron versus palonosetron in combination with aprepitant and dexamethasone for the control of highly emetogenic chemotherapy-induced nausea and vomiting
Annals of Oncology. 2018;29:viii610   Crossref logo
Link1 Link2 Link3

1287 POSTER Palonosetron plus aprepitant and dexamethasone is a highly effective combination to prevent chemotherapy-induced nausea & vomiting after emetogenic chemotherapy
European Journal of Cancer Supplements. 2005;3(2):371-372   Crossref logo
Link1 Link2

Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
Cancer Research and Treatment. 2020;52(3):907-916   Crossref logo
Link1 Link2 Link3

Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy
SpringerPlus. 2016;5(1):   Crossref logo
Link1 Link2 Link3

The Efficacy of Triplet Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients Receiving Highly Emetogenic Chemotherapy: Palonosetron (PALO), Aprepitant (APR), and Dexamethasone (DEX)
Annals of Oncology. 2012;23:ix509   Crossref logo
Link1 Link2

Phase II study of palonosetron, aprepitant and dexamethasone to prevent nausea and vomiting induced by multiple-day emetogenic chemotherapy
Supportive Care in Cancer. 2017;   Crossref logo
Link1 Link2 Link3

Efficacy of Triplet Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients Receiving Highly Emetogenic Chemotherapy: Palonosetron, Aprepitant, and Dexamethasone
Annals of Oncology. 2012;23:xi88   Crossref logo
Link1 Link2

A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)
Annals of Oncology. 2018;29(2):452-458   Crossref logo
Link1 Link2 Link3

Cost-Consequence Analysis of an Aprepitant Regimen Versus a Standard Antiemetic Regimen for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting in Italy
Value in Health. 2014;17(7):A625   Crossref logo
Link1 Link2

Prevention of Chemotherapy-Induced Nausea and Vomiting with a Fixed-Dose Combination of Netupitant and Palonosetron (Nepa) Following Highly Emetogenic Chemotherapy: Evaluation of Response Based on Gender and Age
Annals of Oncology. 2014;25:iv520   Crossref logo
Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.